All In Biotech

Drug Trial Radar · NCT06081621

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

A Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF) Patients

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Dec 11, 2023

Primary completion

Mar 14, 2025

Study completion Mar 14, 2025

Sponsor

Lead sponsor
Regend TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Peking Union Medical College Hospital; RenJi Hospital; Ruijin Hospital; Second Affiliated Hospital of Xiamen Medical College
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • REGEND001Biological

    REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.

  • PlaceboBiological

    Placebo: Sodium chloride injection administrated by bronchoscopy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the area under the curve (AUC) of DLCO measured values at each visit from baseline to week 24 between the REGEND001 group and the placebo group.Time frame: 12 and 24 weeks after treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, China

  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, China

  • Renji Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.